China SXT Pharmaceuticals (China SXT Pharmaceuticals) EBITDA Margin % : -984.79% (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. China SXT Pharmaceuticals's EBITDA for the six months ended in Sep. 2023 was $-9.26 Mil. China SXT Pharmaceuticals's Revenue for the six months ended in Sep. 2023 was $0.94 Mil. Therefore, China SXT Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2023 was -984.79%.

China SXT Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for China SXT Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals EBITDA Margin % Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBITDA Margin %

Get a 7-Day Free Trial

27.81

-19.55

-38.76

-187.16

-271.65

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial									-263.23	-137.40	-82.78	-571.04	-984.79

Competitive Comparison of China SXT Pharmaceuticals's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China SXT Pharmaceuticals's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where China SXT Pharmaceuticals's EBITDA Margin % falls into.

China SXT Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

China SXT Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-5.357	/	1.972
	=	-271.65 %

China SXT Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-9.257	/	0.94
	=	-984.79 %

China SXT Pharmaceuticals (NAS:SXTC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

China SXT Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of China SXT Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

2RY0:Germany

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.